Immunotherapy in Melanoma | Specialty

Dr. Robert on 5-Year Analysis of Dabrafenib/Trametinib in BRAF V600-Mutant Melanoma

June 4th 2019

Caroline Robert, MD, PhD, head of the Dermatology Unit in Gustave Roussy Cancer Center, Villejuif-Paris, France, discusses results of a 5-year analysis evaluating the long-term effects of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF V600–mutant unresectable or metastatic melanoma.

Dr. Johnson on Applications of Immunotherapy in Melanoma

May 30th 2019

Douglas B. Johnson, MD, assistant professor of medicine, Vanderbilt University Medical Center, clinical director, Melanoma Research Program, Vanderbilt-Ingram Cancer Center, discusses applications of immunotherapy in melanoma.

Immunotherapy Lessons Learned in Melanoma May Turn Tide in Other Tumors

May 22nd 2019

The use of immunotherapy in cancer was solidified by the ample activity seen in patients with melanoma.

Dr. Daud Discusses the Immunogenicity of Melanoma

May 17th 2019

Adil Daud, MD, clinical professor, Department of Medicine, director, Melanoma Clinical Research, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the immunogenicity of melanoma.

Dr. Whitman on Expanding the Benefit of Immunotherapy in Solid Tumors

May 17th 2019

Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses ways to expand the benefit of immunotherapy in non-immunogenic solid tumors.

Dr. Sullivan on Immunotherapy Approaches in Melanoma

April 29th 2019

Ryan J. Sullivan, MD, assistant professor of medicine, Harvard Medical School, assistant professor of hematology/oncology, Massachusetts General Hospital, discusses treatment approaches with immunotherapy for patients with melanoma.

Cemiplimab Nears EU Approval for CSCC

April 29th 2019

The European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of cemiplimab for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation, according to Regeneron Pharmaceuticals, the manufacturer of the PD-1 inhibitor.

Dr. Sullivan on Findings From the ENCORE 601 Trial in Melanoma

April 10th 2019

Ryan J. Sullivan, MD, instructor of medicine, Harvard Medical School, assistant in medicine, Massachusetts General Hospital (MGH), MGH Cancer Center, discusses findings from the ENCORE 601 trial in melanoma.

Dr. Johnson on Promise of Combination Therapy in Melanoma

April 5th 2019

Douglas B. Johnson, MD, assistant professor of medicine, Vanderbilt University Medical Center, clinical director, Melanoma Research Program, Vanderbilt-Ingram Cancer Center, discusses the promise of combination therapy in patients with melanoma.

Dr. Olszanski Discusses Advances in Stage III Melanoma

March 30th 2019

Anthony J. Olszanski, MD, RPh, vice chair, Department of Hematology/Oncology, director, Early Drug Development Phase I Program, Fox Chase Cancer Center, discusses treatment advances in stage III melanoma.

Emerging Approaches for BRAF-Mutant Metastatic Melanoma

March 28th 2019

Treatment Sequencing in BRAF+ Metastatic Melanoma

March 28th 2019

Treatment Adherence and Response With BRAF-Targeted Therapy

March 28th 2019

BRAF/MEK Frontline Therapy in Metastatic Melanoma

March 28th 2019

Maximizing BRAF/MEK Inhibition in Melanoma

March 28th 2019

Recommendations for Managing BRAF+ Metastatic Melanoma

March 28th 2019

BRAF-Targeted Therapy in Melanoma: Toxicity Management

March 28th 2019

Treating Melanoma Patients With BRAF/MEK Dual-Targeted Therapy

March 28th 2019

The COLUMBUS Trial in BRAF-Mutant Melanoma

March 28th 2019

BRAF/MEK Combinations Available in Advanced Melanoma

March 28th 2019